The Board of Regents of the University of Oklahoma
发明人:
David Charles Kem,Xichun Yu,Hongliang Li,LaTasha B. Craig
申请号：
US16274944
公开号：
US20190263862A1
申请日:
2019.02.13
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs.
